Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

por Palmieri, C, Gojis, O, Rudraraju, B, Stamp-Vincent, C, Wilson, D, Langdon, S, Gourley, C, Faratian, D
Publicado 2013

C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target

por Katz, E, Faratian, D, Bartlett, JMS, MacLeod, K, Pedersen, H, Larionov, A, Smith, EM, Howell, AP, Dixon, JM, Evans, EE, Langdon, SP, Harrison, DJ
Publicado 2008

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

por Sims, A H, Zweemer, A JM, Nagumo, Y, Faratian, D, Muir, M, Dodds, M, Um, I, Kay, C, Hasmann, M, Harrison, D J, Langdon, S P
Publicado 2012

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk

por Katz, E, Dubois-Marshall, S, Sims, A H, Faratian, D, Li, J, Smith, E S, Quinn, J A, Edward, M, Meehan, R R, Evans, E E, Langdon, S P, Harrison, D J
Publicado 2010